B Biogen
American multinational biotechnology company
Updates & Highlights
Investing.com India · about 3 hours ago
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome
Stock Titan · about 3 hours ago
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News
Quiver Quantitative · about 15 hours ago
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients
Recent Openings
View all 1 jobs arrow_forwardMachine Learning Engineer, Operations and Health Systems Research
location_on Cambridge, MA, US
All Jobs
Machine Learning Engineer, Operations and Health Systems Research
location_on Cambridge, MA, US
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Parental Leave
Family-friendly policies
Competitive Salary
Market-rate compensation
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Biogen?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentStoke, Biogen present 4-year zorevunersen data for Dravet syndrome
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome
Investing.com India · about 3 hours ago
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News
Stock Titan · about 3 hours ago
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients
Quiver Quantitative · about 15 hours ago
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Yahoo Finance · 4 days ago
Biogen enlists lupus patient advocate to share social media story of resilience
Biogen enlists lupus patient advocate to share social media story of resilience
Fierce Pharma · 4 days ago
Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Biogen · 5 days ago
Ionis, Biogen deliver new tau data in Alzheimer’s
Ionis, Biogen deliver new tau data in Alzheimer’s
Longevity.Technology · 5 days ago
Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home?
Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home?
simplywall.st · 6 days ago
When Biogen Switches Platforms, Your Site Feels It First
When Biogen Switches Platforms, Your Site Feels It First
The Clinical Trial Vanguard · 6 days ago
Biogen entscheidet sich für Veeva Vault CRM
Biogen entscheidet sich für Veeva Vault CRM
PR Newswire · 7 days ago
Biogen Inc. stock outperforms competitors on strong trading day
Biogen Inc. stock outperforms competitors on strong trading day
MarketWatch · 7 days ago
Veeva stock gains as Biogen selects Vault CRM globally
Veeva stock gains as Biogen selects Vault CRM globally
Investing.com India · 7 days ago
Biogen commits to Veeva Vault CRM platform globally
Biogen commits to Veeva Vault CRM platform globally
Investing.com · 7 days ago
RBC Capital raises Biogen stock price target on lupus drug potential
RBC Capital raises Biogen stock price target on lupus drug potential
Investing.com · 7 days ago
Biogen adopts Veeva Vault CRM to accelerate med...
Biogen adopts Veeva Vault CRM to accelerate med...
Pluang · 7 days ago
Biogen selects Veeva Vault CRM for global commercial operations
Biogen selects Veeva Vault CRM for global commercial operations
StreetInsider · 7 days ago
Veeva Vault CRM Selected by Biogen
Veeva Vault CRM Selected by Biogen
PR Newswire · 7 days ago
RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating
RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating
marketscreener.com · 7 days ago
Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S.
Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S.
Quiver Quantitative · 8 days ago
How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones
How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones
simplywall.st · 10 days ago